Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

SOLACEA-H in Heparin-sparing Haemodialysis

NCT: NCT06281028 · COMPLETED

NCT IDNCT06281028
StatusCOMPLETED
Start Date2024-11-20
Completion2026-02-02
SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche (OTHER)
First posted
Last updated

Brief Summary

The aim of the study is to evaluate the efficacy of the SOLACEA-H dialyser, particularly in patients at high risk of haemorrhage, during post-dilution haemodiafiltration sessions with complete or partial heparin sparing. It will be compared with another dialyser (HYDROLINK-NVU)

Frequently Asked Questions

What is SOLACEA-H in Heparin-sparing Haemodialysis?

SOLACEA-H in Heparin-sparing Haemodialysis is a clinical trial registered under NCT06281028. Current status: COMPLETED.

What is the status of NCT06281028?

The current status of NCT06281028 (SOLACEA-H in Heparin-sparing Haemodialysis) is: COMPLETED.

When did SOLACEA-H in Heparin-sparing Haemodialysis start?

SOLACEA-H in Heparin-sparing Haemodialysis started on 2024-11-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑